Hosted on MSN5mon
Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term TrialsQWINT-1 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin glargine for 52 weeks in insulin naïve patients. The trial met its primary endpoint of non ...
The Associated Press on MSN20d
Newsom Committed California to Making Its Own Insulin. It’s at Least a Year Behind His ScheduleGov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind schedule ...
Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...
News Medical on MSN5d
Revolutionizing diabetes care with innovative targets and therapeutic optionsA thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...
28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...
Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback